RAC 2.92% $1.94 race oncology ltd

Ann: Quarterly Activity Report & Appendix 4C, page-79

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    This comparative analysis is not intended as financial advice. You are encouraged to do your own research and make your own investment decisions. 
Disclosures - held, sentiment bullish/long. This is my own analysis and I have not received compensation for it.
    If RACE pulls off a strong partnership in my opinion I think a share price at least $17 is justified.

    This would be a market cap around AUD $3B ( RACE's market cap is currently $478M ).

    Screen Shot 2021-08-04 at 10.52.03 pm.png

    For another (non-partnership) scenario look at the recent buyout of Synthorx which was 16 months before the trial reported any results. Equivalent value around $20 per share and a drug category with a fraction of the revenue potential of Bisantrene as an FTO inhibitor.


    Screen Shot 2021-08-04 at 10.55.01 pm.png
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.